Objective-dl-Nebivolol, a selective β1-adrenergic receptor antagonist, besides its hypotensive activity exerts vasodilatory and platelet inhibitory effects in vitro by a mechanism involving nitric oxide (NO). Our aim was to evaluate whether nebivolol exerts in vivo antithrombotic effects, to unravel the mechanism of this action and to clarify the relative roles of its 2 enantiomers: d-and l-nebivolol. Methods and Results-In wild-type mice, dl-nebivolol, l-nebivolol, and d-nebivolol, but not bisoprolol, reduced mortality consequent to platelet pulmonary thromboembolism induced by the intravenous injection of collagen plus epinephrine (−44%, −45%, −29%, respectively; P<0.05), whereas in eNOS −/− mice only dl-nebivolol and d-nebivolol were effective. dl-Nebivolol, l-and d-nebivolol reduced photochemical damage-induced femoral artery thrombosis in wild-type mice, whereas in eNOS −/− mice only dl-nebivolol and d-nebivolol were active. Moreover, dl-nebivolol and l-nebivolol increased plasma, urinary-, and platelet-derived nitrites and nitrates (NOx), NO degradation products, in wild-type but not in eNOS −/− mice. In vivo platelet activation, assessed by platelet P-selectin expression, was reduced by dl-nebivolol and l-and dnebivolol in wild-type mice but only by dl-nebivolol and d-nebivolol in eNOS −/− mice. In bone marrow-transplanted, chimeric mice with only blood cells, and not the endothelium, producing NO dl-nebivolol and l-nebivolol maintained their antithrombotic activity, whereas they lose it in chimeras with only endothelium, and not blood cells, producing NO. In vitro, with isolated platelets, dl-nebivolol and l-nebivolol, but not d-nebivolol and bisoprolol, increased platelet cGMP and NOx formation. Treatment with dl-nebivolol and l-nebivolol increased phophorylated eNOS in platelets. Conclusions-Our data show that dl-nebivolol exerts an antithrombotic activity by stimulating the formation of NO by platelets, and that this effect is generated by its l-enantiomer, whereas the d-enantiomer exerts a weak antiplatelet effect because of β−adrenergic receptor-independent stimulation of adenyly cyclase. These results confirm that platelet-derived NO plays a role in thrombosis prevention and it may represent a target of pharmacological intervention. (Arterioscler Thromb Vasc Biol. 2014;34:820-829.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
H ypertension is associated with an increased risk of arterial thrombotic events, such as stroke and myocardial infarction, 1 in which platelets are deeply involved. Previous studies have shown that β-adrenoceptor blockers reduce platelet activation and aggregation, 2 but this does not seem to be a class effect because not all β-blockers share this property. 3 dl-Nebivolol (a racemic mixture of d-and l-nebivolol) is a third-generation β 1 adrenoceptor-selective antagonist that, besides its β-blockade-mediated hypotensive effect, possesses direct vasodilatory properties through a mechanism involving the l-arginine/nitric oxide (NO) pathway. 4, 5 Of the 2 enantiomers forming the racemic mixture of dl-nebivolol, d-nebivolol, which has an ≈200-fold greater affinity for β 1 -adrenoceptors than that of l-nebivolol, seems to be mainly responsible of selective β-blockade, 6 whereas the l-form is the main effector of the endothelium-dependent vasorelaxant effect. 7, 8 dl-Nebivolol exerts its vasodilatory action by activating endothelial nitric oxide synthase (eNOS) and by preventing eNOS uncoupling, thus enhancing NO production. 9 Endothelium-derived NO is a powerful inhibitor of platelet activation and an antithrombotic agent. 10, 11 Besides endothelium, eNOS is present in other cells, including platelets, [12] [13] [14] and several in vitro and in vivo observations in animals and in humans suggest that platelet-derived NO plays a significant anti-inflammatory and antithrombotic role. [15] [16] [17] [18] [19] dl-Nebivolol was previously reported to inhibit ADP-and collagen-induced aggregation of human platelets in vitro, 20 an effect prevented by the previous exposure of platelets to a NOS inhibitor, such as L-NG-nitroarginine methyl ester, and enhanced by preincubation with l-arginine, the substrate of NOS, suggesting that the antiplatelet effect of dl-nebivolol is mediated by an enhanced release of NO from platelets. 4 Despite these premises, no data are available yet on the antithrombotic activity of dl-nebivolol in vivo and on the potential role of platelet-derived NO in it. Therefore, the aim of our study was to assess whether dl-nebivolol exerts an antithrombotic effect, to test which of its 2 enantiomers, d-and l-nebivolol, is responsible for this activity, and to evaluate the role of plateletversus endothelium-derived NO in its antithrombotic activity.
Methods
Materials and Methods are available in the online-only Supplement.
Results

Antithrombotic Activity
Pulmonary Thromboembolism
The intravenous injection of collagen plus epinephrine led to death 85% of wild-type mice. Pretreatment with dl-nebivolol dose dependently reduced mortality, whereas bisoprolol was ineffective ( Figure II in the online-only Data Supplement). dl-Nebivolol (5 mg/kg) and equimolar doses of l-nebivolol (2.5 mg/kg) reduced mortality equally (−44% and −45%, respectively; P<0.05 versus controls), whereas d-nebivolol (2.5 mg/ kg) was less effective (−29%; Figure 1A and 1C).
The dose of collagen plus epinephrine required to obtain ≈85% mortality in eNOS −/− mice was lower than that required in wild-type mice (Materials and Methods are available in the online-only Data Supplement). dl-Nebivolol (5 mg/kg) and, slightly, d-nebivolol (2.5 mg/kg) protected also eNOS −/− mice from collagen plus epinephrine-induced mortality, but less than wild-type mice, whereas l-nebivolol (2.5 mg/kg) completely lost its protective activity in this animal strain ( Figure 1B and 1C) .
dl-Nebivolol (5 mg/kg) and even more l-nebivolol (2.5 mg/ kg) protected wild-type mice also from mechanical pulmonary microembolism induced by the intravenous injection of swollen, hardened rat red blood cells ( Figure 1D ), indicating that a vasodilatory effect on lung microvasculature contributes to the protective action of dl-nebivolol and l-nebivolol against lung embolism-provoked lethality. This effect was not shared by d-nebivolol and bisoprolol.
Femoral Artery Thrombosis
Photochemically induced injury to the femoral artery of wildtype mice led to the complete arrest of blood flow in 11.9±0.7 minutes. Pretreatment with dl-nebivolol, l-nebivolol, and d-nebivolol significantly prolonged the time to occlusion, whereas bisoprolol was ineffective ( Figure 2A ). Thrombus weight was significantly lower in the groups treated with dland l-nebivolol, whereas d-nebivolol and bisoprolol were ineffective ( Figure 2B ). In eNOS −/− mice, photochemical injury to the femoral artery led to the complete arrest of blood flow in a time significantly shorter than that of wild-type mice (7.7±0.33 minutes; P<0.05 versus wild-type mice). dl-nebivolol and d-nebivolol still prevented thrombosis in eNOS −/− mice, whereas l-nebivolol lost its protective effect; here too, bisoprolol was inactive ( Figure 2C ).
Thrombus weight was significantly higher in vehicle-treated, control eNOS −/− mice when compared with that in wild-type mice (0.59±0.02 versus 0.27±0.01; P<0.05). dl-Nebivolol and d-nebivolol reduced thrombus weight, whereas l-nebivolol and bisoprolol were ineffective ( Figure 2D ).
Venous Thrombosis
After the provocation of inferior vena cava flow restriction, all (n=5) wild-type mice developed a thrombus located just below the ligature (toward the tail) within 48 hours (thrombus weight, 13.4±4.8 mg and length, 4.8±1.5 mm). Pretreatment with dl-nebivolol and l-nebivolol reduced significantly venous thrombus size (dl-nebivolol: thrombus weight, 4.5±1.5 mg; thrombus length, 3.7±1.9 and l-nebivolol: thrombus weight, 6.2±2.7 mg; thrombus length, 3.0±1.2; P=0.019 and P=0.04 versus control, respectively). Pretreatment with d-nebivolol did not significantly affect venous thrombosis (thrombus weight, 9.2±3.3 mg; thrombus length, 4.1±2.0; P=NS). These results are in line with the pivotal role played by NO in the regulation of venous endothelial function contributing to prevent venous thrombosis. 21
Platelet Inhibition
Platelet Aggregation
Treatment with dl-nebivolol, d-nebivolol, and, even more, l-nebivolol inhibited significantly ex vivo U46619-induced platelet aggregation ( Figure 3A ). In vitro, U46619-induced platelet aggregation was significantly inhibited by preincubation with dl-nebivolol, l-nebivolol, and d-nebivolol (efficacy: dl>l>d).
To evaluate which β-receptors mediate the inhibitory activity of nebivolol on platelets, we performed in vitro coincubation experiments with selective β1 (CGP20712A) or β2 (ICI118551) adrenoreceptor antagonists. The inhibitory effect of d-nebivolol was not affected by CGP20712A or ICI118551, whereas the inhibitory effect of dl-and l-nebivolol was completely abolished by CGP20712A but not by ICI118551 ( Figure 3B ), indicating that the in vitro inhibitory effects of dl-and l-nebivolol on platelets are mediated by β1-adrenergic receptors (ARs). On the contrary, the inhibitory effect of d-nebivolol on platelet aggregation was abolished by pretreatment with SQ 22 536, an inhibitor of adenylyl cyclase ( Figure 3C ). Consistently, incubation of platelets with d-nebivolol, but not with dl-and l-nebivolol, enhanced intraplatelet cAMP ( Figure 3D ). However, l-nebivolol-induced inhibition of platelet aggregation was abolished by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, a soluble guanylyl cyclase inhibitor ( Figure 3C ).
Platelet P-Selectin Expression
The expression of P-selectin on circulating platelets was significantly enhanced by the intravenous injection of a mixture of collagen plus epinephrine in wild-type mice and even more strikingly in eNOS −/− mice (Table) . Pretreatment with dl-nebivolol, l-nebivolol and, to a lesser extent, d-nebivolol significantly reduced platelet P-selectin expression in wildtype mice (Table) . The first-generation β-blocker bisoprolol (5 mg/kg PO) also slightly, but not significantly, reduced platelet P-selectin expression in wild-type animals, and not as much as dl-nebivolol and its enantiomers. In eNOS −/− mice, only dl-nebivolol and d-nebivolol reduced slightly, but significantly, platelet P-selectin expression, whereas l-nebivolol and bisoprolol were not effective (Table) .
NO Stimulation
Nitrites and Nitrates (NOx)
The treatment of wild-type mice with l-nebivolol (2.5 mg/kg) for 5 days significantly increased plasmatic and urinary NOx; dl-nebivolol slightly, but not significantly, increased NOx, whereas d-nebivolol and bisoprolol did not ( Figure 4A nitrites and nitrates were induced by any treatment (not shown).
Intraplatelet cGMP
The treatment of mice with either dl-nebivolol or l-nebivolol significantly increased intraplatelet cGMP, whereas d-nebivolol and bisoprolol were ineffective ( Figure 4C ).
Pretreatment with the NO scavenger v2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide significantly reduced dl-nebivolol and l-nebivolol-induced intraplatelet cGMP increase ( Figure 4C ).
Role of Platelet-Derived NO
Femoral Artery Thrombosis in Chimeric Mice
To unravel the role of platelet-versus endothelium-derived NO in the protective effects of dl-nebivolol against femoral artery thrombosis, we studied chimeric mice with circulating blood cells derived from eNOS −/− mice and with blood vessels normally expressing eNOS (wild-type chimeric mice) or vice versa chimeric mice with circulating blood cells normally expressing eNOS and blood vessels devoid of eNOS (eNOS −/− chimeric mice). The time to complete occlusion of the femoral artery in wild-type chimeric mice (in which circulating cells are not able to produce NO) was significantly shorter than that of wild-type mice (8.1±1.85 versus 11.9±0.7 minutes; P<0.05), and it was slightly but significantly prolonged by dl-nebivolol or d-nebivolol, but not by l-nebivolol ( Figure 5A ). In eNOS −/− chimeric mice (in which circulating cells produced NO but the endothelium did not), the time to complete occlusion of the femoral artery was slightly, but significantly, longer than that of eNOS −/− mice (9.66±1.7 versus 7.7±0.33 minutes; P<0.001) and not different from that of wild-type mice, and it was significantly prolonged by the administration of both dl-nebivolol and l-nebivolol but not by d-nebivolol ( Figure 5B ). Control transplanted mice (wild type into wild type and eNOS −/− into eNOS −/− ) behaved as the respective not transplanted strains.
To unravel the possible role of the interaction with white cells, thrombosis was induced in wild-type mice depleted of neutrophils and reinfused with neutrophils isolated from eNOS −/− mice. The resultant chimeric mice had normal circulating platelets but neutrophils lacking eNOS. In these conditions, although a slight, not significant, prolongation of the time to thrombotic occlusion of the femoral artery was observed, the antithrombotic effect of dl-nebivolol and l-nebivolol was fully preserved ( Figure III in the online-only Data Supplement).
Production of NO From Isolated Platelets
When platelets isolated from mice treated for 5 days with the different drugs were stimulated in vitro with collagen, NOx in the supernatant were significantly higher in mice treated with dl-nebivolol and l-nebivolol but not with d-nebivolol and bisoprolol ( Figure 4D ). Moreover, incubation in vitro of platelets with dl-and l-nebivolol (100 μmol/L), but not with d-nebivolol, increased the amount of nitrites and nitrates found in the supernatant of collagen-stimulated platelets ( Figure 4E ). Incubation of GFP in vitro with dl-and l-nebivolol also increased intraplatelet cGMP, an effect blocked by preincubation with ODQ, whereas d-nebivolol was ineffective ( Figure IV 
Other effects
Blood Pressure eNOS-knockout mice had increased blood pressure (130±1.9 mm Hg) when compared with wild-type mice (119±3.1 mm Hg). 22 In eNOS −/− mice, dl-nebivolol and d-nebivolol significantly reduced blood pressure, whereas l-nebivolol did not ( Figure 7A ). Bisoprolol was also effective. In wild-type normotensive mice, only D-nebivolol reduced blood pressure ( Figure 7B ). 
Antioxidant Activity
Discussion
Our data show that dl-nebivolol, a third-generation, highly selective β 1 -ARs antagonist, exerts an antithrombotic activity in vivo in mice by enhancing NO release from platelets and that the NO-releasing activity can be ascribed mainly to its l-enantiomer by β-AR-mediated eNOS activation. dl-Nebivolol dose dependently protected wild-type mice from platelet-mediated pulmonary thromboembolism induced by the intravenous injection of collagen plus epinephrine. In this model, l-nebivolol was as effective as the racemic mixture and more than d-nebivolol. Moreover, dl-and l-nebivolol, but not d-nebivolol, exerted a partial protective effect also in a model of mechanical pulmonary microembolism induced by the intravenous injection of swollen, hardened rat red blood cells. In this model, vasodilatory agents, such as calcium antagonists or isosorbide mononitrate, but not antiplatelet agents, exert a protective effect by inducing vasodilation of the lung microvasculature. 23 These results are thus consistent with both an antiplatelet and a vasodilatory activity of dl-and l-nebivolol, which concur to prevent collagen plus epinephrine-induced pulmonary embolism lethality. However, the antithrombotic effect of dl-and l-nebivolol was confirmed in a photochemical injury-induced arterial thrombosis model, known to be platelet mediated 24 and not influenced by vasodilators. The central role of the antiplatelet activity of dl-nebivolol and l-nebivolol in the antithrombotic effects is confirmed by the inhibition of ex vivo and in vitro platelet aggregation and by the reduction of the expression of P-selectin on the surface of circulating platelets.
A platelet inhibitory activity of dl-nebivolol was previously shown in vitro and found to be enhanced by l-arginine, suggesting a role of NO. 20 We confirm and extend these observations: the inhibition of soluble guanylyl cyclase abolished the in vitro inhibitory activity of l-nebivolol on platelet aggregation, but not that of d-nebivolol that was instead attenuated by the inhibition of adenylyl cyclase, suggesting a different mechanism of action of the 2 enantiomers on platelets.
To establish whether also the antithrombotic effects of dl-nebivolol could be ascribed to an increase of NO production, we performed experiments in eNOS −/− mice, genetically deficient of the endothelial variant of NO-synthase. 25 In these mice, l-nebivolol lost its protective effect: these results show that l-nebivolol requires a functional eNOS to exert its antithrombotic activity and acts by stimulating NO production. Confirmatory evidence comes from the finding that dl-nebivolol and, more strikingly, l-nebivolol induced an in vivo enhancement of plasmatic and urinary nitrites and nitrates, the main end products of NO catabolism. 26 The increased levels of NO attained in vivo were biologically relevant, as documented by the enhanced intraplatelet cGMP detected in mice treated with l-nebivolol, an effect caused by enhanced NO-formation because pretreatment with v2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide, a NO scavenger, 27 abolished it. In agreement with the present results, an increase in plasmatic cGMP was previously shown in patients with hypertension treated with dl-nebivolol (5 mg/d for 4 weeks) but not with hydrochlorothiazide (25 mg/d for 4 weeks). 28 NO in the circulation is produced both by the endothelium and by blood cells. However, the presence and role of eNOS in platelets have been the object of debate. Since the first report by Radomski et al, 13 showing an increase of cGMP in isolated platelets stimulated by collagen, an effect abrogated by NOS antagonists, numerous studies have confirmed the presence of eNOS in platelets, the ability to synthesize NO, and the inhibitory role on platelet activation. 29 However, other reports have negated the presence of eNOS in platelets 30 and 1 group has even provided evidence that platelet-derived NO and its second messenger, cGMP, have a stimulatory role on platelet activation. 31 Similarly, studies on the role of platelet-derived NO in thrombosis models in vivo have given conflicting results, with data in favor of a significant antithrombotic effect, 15, 16 studies suggesting that the absence of platelet eNOS has little consequence on arterial thrombus formation, 32, 33 and even studies showing an impaired ability of eNOS −/− mice to form occlusive thrombi. 34 Differences in experimental conditions and animal models may probably explain the conflicting results. Moreover, the existence of variant forms of eNOS in platelets may explain some of the negative data. 30, 35 Despite controversy, consistent data suggest that platelet-derived NO participates in platelet inhibition and thrombosis prevention and that conditions characterized by defective platelet NO production, such as hypertension or treatment with some antiretroviral drugs, are associated with an enhanced risk of ischemic cardiovascular events. 18, 19, 36 Recent data showing impaired cGMP formation and enhanced platelet reactivity in patients with myocardial infarction carrying 2 gene mutations affecting soluble guanylyl cyclase function confirm the importance of NO-mediated platelet inhibition in the prevention of thrombosis. 37 Therefore, to clarify the role of platelet-derived NO in the antithrombotic effects of dl-nebivolol, we used chimeric mice. dl-Nebivolol and l-nebivolol maintained their antithrombotic action in mice in which blood cells, but not the endothelium, produce NO (wild-type chimeras), whereas they lost it in mice in which only endothelial cells produce NO. A confirmation of the ability of dl-and l-nebivolol to induce NO release from platelets comes from the finding that platelets isolated from wild-type mice treated with dlnebivolol or l-nebivolol, but not with d-nebivolol or bisoprolol, and stimulated in vitro with collagen release increased amounts of NO and that incubation in vitro with l-nebivolol enhances NO release in the supernatant and intraplatelet cGMP, an effect prevented by soluble guanylyl cyclase inhibition. Experiments in wild-type mice depleted of neutrophils and reinfused with neutrophils isolated from eNOS −/− mice, showing that the antithrombotic effect of l-nebivolol is fully preserved, further point to platelets as the main effectors of l-nebivolol-induced NO release in vivo.
dl-Nebivolol was reported to possess an intrinsic β2/β3 agonistic activity, 5, [38] [39] [40] leading to Akt-dependent phosphorylation of eNOS in Ser1177 in endothelial cells 41 ; therefore, we assessed phosphorylated eNOS in platelets. dl-Nebivolol and l-nebivolol enhanced eNOS phosphorylation at serine1177, 1 of the phosphorylation sites involved in eNOS activation in platelets. [42] [43] [44] Tran Quang et al 45 showed that both d-and l-nebivolol stimulate vascular β3-adrenoceptors in rat aortae, and that this may be relevant to nebivolol-induced NO release. However, the presence of β3-AR has not been demonstrated in platelets that instead possess β1-and β2-AR. Therefore, we tested whether the antiplatelet effects of nebivolol are affected by selective β1 and β2 antagonists. The in vitro platelet inhibitory effect of l-nebivolol was prevented by both β1/ β2 antagonists, whereas that of d-nebivolol was not. In fact, d-nebivolol exerted a weak antiplatelet effect independent from NO and related to a β-AR-independent stimulation of adenylyl cyclase, as shown by the neutralizing action of the adenylyl cyclase inhibitor SQ 22 536. However, this effect seems to contribute marginally to the antithrombotic activity of dl-nebivolol in wild-type mice, in which l-nebivolol was as effective as the racemic mixture.
Nebivolol was recently shown to act as a G-protein-coupled receptor kinase/β-arrestin biased agonist 46 : whether this effect is involved in either adenylyl cyclase or eNOS activation in platelets remains to be established.
In conclusion, our data show for the first time that dl-nebivolol, and in particular its l-enantiomer, exerts an antithrombotic and antiplatelet effect in vivo by stimulating the release of NO from platelets.
The pre-eminent role of platelet-instead of endothelium-derived NO in the antithrombotic activity of dlnebivolol suggests that NO generated by platelets upon activation at an arterial damage site is more effective than that generated by endothelium-derived NO probably because it acts exactly where platelets get activated.
These observations suggest that the modulation of NO production from platelets, as well as the sensitization of platelets to the inhibitory effects of NO, 44 may be important targets of future antithrombotic therapies. For instance, some statins were shown to display part of their pleiotropic antiatherothrombotic activity by stimulating platelet eNOS to produce NO. 47, 48 Stimulation of platelet-derived NO may be of particular value in conditions of severe endothelial dysfunction in which interventions aimed at restoring impaired NO production may be inefficacious. 22 It is important to note that the doses of dl-nebivolol and its enantiomers effective in our models span between 0.34 and 2.7μg/cm 2 when normalized for body surface area, an index which best correlates biological parameters across different mammalian species 49 : these doses are close to those used in humans (the therapeutic dose of 5 mg/d for a man of ≈70 kg of body weight corresponds to 0.27 μg/cm 2 ).
The observation that dl-nebivolol reduced significantly all-cause mortality in elderly patients with congestive heart failure of ischemic etiology, whereas first-generation antihypertensive β-blockers do not prevent ischemic cardiovascular events when compared with other antihypertensive interventions, 50 suggests that increased platelet-derived NO production in vivo may confer enhanced cardiovascular protection.
However, only large, prospective comparative clinical trials with other β-blockers not influencing NO production may confirm whether these additional pleiotropic effects of dl-nebivolol on the cardiovascular system confer a superior profile in terms of prevention of ischemic cardiovascular events.
